A clinical-stage immuno-oncology company known as Agenus Inc. has been making waves in the United States and around the world with its discovery and development of immuno-oncology products. This innovative company is behind Retrocyte Display, an antibody expression platform that aids in the identification of fully human and humanized monoclonal antibodies, and several other display technologies. Agenus is also behind QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant that could revolutionize vaccination. Currently, Agenus is in various stages of developing several impactful cancer treatments, including Balstilimab, an anti-PD-1 antagonist that is completed Phase II clinical trials to treat second-line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trials; and AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trials. Other products that Agenus is developing include AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trials; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trials; BMS-986442, a TIGIT bispecific antibody; AGEN1327, a human monoclonal antibody; INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trials for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks and has partnered with Bristol-Myers Squibb, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. Founded in 1994, Agenus Inc. is headquartered in Lexington, Massachusetts, and has been behind some of the most promising cancer treatments of the 21st century.
Agenus's ticker is AGEN
The company's shares trade on the NASDAQ stock exchange
They are based in Lexington, Massachusetts
There are 201-500 employees working at Agenus
It is agenusbio.com
Agenus is in the Healthcare sector
Agenus is in the Biotechnology industry
The following five companies are Agenus's industry peers: